Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?

20 Jul 2015

Abstract excerpt

UNLABELLED: Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic neoplasms that are driven by somatically acquired genetic mutations and epigenetic alterations. Accurate risk stratification is essential for delivery of risk-adaptive therapeutic interventions. The current prognostic tools sum the impact of clinical, pathologic, and laboratory parameters. Newer technologies with next-generation targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Genomics and Rare Diseases
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26194858
DOI: 10.1634/theoncologist.2015-0067

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?PMID 26194858Read ↗

Current state of prognostication and risk stratification in myelodysplastic syndromes.Semantic proximity Read ↗

The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.Semantic proximity Read ↗

The genetic basis and expanding role of molecular analysis in the diagnosis, prognosis, and therapeutic design for myelodysplastic syndromes.Semantic proximity Read ↗

Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation.Semantic proximity Read ↗

Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.Semantic proximity Read ↗

New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice.Semantic proximity Read ↗

New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.Semantic proximity Read ↗

Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges.Semantic proximity Read ↗

Molecular pathophysiology of myelodysplastic syndromes.Semantic proximity Read ↗

Genetic basis of myelodysplastic syndromes.Semantic proximity Read ↗

Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help?Semantic proximity Read ↗

Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.